JP2002508320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002508320A5 JP2002508320A5 JP2000538687A JP2000538687A JP2002508320A5 JP 2002508320 A5 JP2002508320 A5 JP 2002508320A5 JP 2000538687 A JP2000538687 A JP 2000538687A JP 2000538687 A JP2000538687 A JP 2000538687A JP 2002508320 A5 JP2002508320 A5 JP 2002508320A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- statin
- kit
- mevastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 27
- 150000003839 salts Chemical class 0.000 description 21
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 20
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 20
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 20
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 19
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 19
- 238000000034 method Methods 0.000 description 15
- -1 carboxyalkyl ether Chemical compound 0.000 description 14
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 11
- 229950009116 mevastatin Drugs 0.000 description 11
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 10
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 10
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 10
- 229960005110 cerivastatin Drugs 0.000 description 10
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- 229960003765 fluvastatin Drugs 0.000 description 10
- 229960004844 lovastatin Drugs 0.000 description 10
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 10
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 10
- 229960002965 pravastatin Drugs 0.000 description 10
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 10
- 229960002855 simvastatin Drugs 0.000 description 10
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 9
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 9
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229950003040 dalvastatin Drugs 0.000 description 9
- VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 description 8
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 6
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 229960005370 atorvastatin Drugs 0.000 description 6
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937597P | 1997-12-12 | 1997-12-12 | |
| US60/069,375 | 1997-12-12 | ||
| PCT/US1998/024679 WO1999030704A1 (en) | 1997-12-12 | 1998-11-20 | Statin-carboxyalkylether combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002508320A JP2002508320A (ja) | 2002-03-19 |
| JP2002508320A5 true JP2002508320A5 (enExample) | 2006-01-19 |
Family
ID=22088573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000538687A Pending JP2002508320A (ja) | 1997-12-12 | 1998-11-20 | スタチン−カルボキシアルキルエーテル配合物 |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1045691B1 (enExample) |
| JP (1) | JP2002508320A (enExample) |
| KR (1) | KR20010033003A (enExample) |
| AR (1) | AR017851A1 (enExample) |
| AT (1) | ATE285762T1 (enExample) |
| AU (1) | AU754089B2 (enExample) |
| BR (1) | BR9813542A (enExample) |
| CA (1) | CA2304612A1 (enExample) |
| CO (1) | CO4970816A1 (enExample) |
| CR (1) | CR5926A (enExample) |
| CU (1) | CU20000140A7 (enExample) |
| DE (1) | DE69828442T2 (enExample) |
| DK (1) | DK1045691T3 (enExample) |
| ES (1) | ES2230733T3 (enExample) |
| GT (1) | GT199800196A (enExample) |
| HN (1) | HN1998000185A (enExample) |
| HU (1) | HUP0004547A3 (enExample) |
| IL (1) | IL135349A0 (enExample) |
| IS (1) | IS2150B (enExample) |
| MY (1) | MY118381A (enExample) |
| NO (1) | NO20002966L (enExample) |
| NZ (1) | NZ503982A (enExample) |
| PA (1) | PA8464601A1 (enExample) |
| PE (1) | PE20000017A1 (enExample) |
| PL (1) | PL341066A1 (enExample) |
| PT (1) | PT1045691E (enExample) |
| SV (1) | SV1998000146A (enExample) |
| UY (1) | UY25299A1 (enExample) |
| WO (1) | WO1999030704A1 (enExample) |
| ZA (1) | ZA9811348B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105154A1 (en) | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| PL343851A1 (en) * | 1997-12-12 | 2001-09-10 | Warner Lambert Co | Antihyperlipidemic statin-lp(a) inhibitor combinations |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| PT1117392E (pt) * | 1998-09-30 | 2004-07-30 | Warner Lambert Co | Metodo para impedir ou atrasar a revascularizacao por cateter |
| US6562864B1 (en) * | 1999-09-02 | 2003-05-13 | Drake Larson | Catechin multimers as therapeutic drug delivery agents |
| IN191580B (enExample) * | 1999-12-17 | 2003-12-06 | Ranbaxy Lab Ltd | |
| PL357076A1 (en) | 2000-01-25 | 2004-07-12 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| AU2001256278A1 (en) * | 2000-04-18 | 2001-10-30 | Bayer Aktiengesellschaft | Use of cse inhibitors for treating heart failure |
| MXPA02009662A (es) * | 2000-04-26 | 2003-03-10 | Warner Lambert Co | Agentes antihipertensivos y su uso. |
| US6689807B1 (en) * | 2000-06-08 | 2004-02-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | HMG CoA reductase inhibitors for promoting angiogenesis |
| KR20040026705A (ko) | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
| IL160077A0 (en) * | 2001-08-16 | 2004-06-20 | Teva Pharma | Processes for preparing calcium salt forms of statins |
| US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| AU2013207423B2 (en) * | 2012-01-06 | 2017-10-12 | Gemphire Therapeutics Inc. | Methods of reducing risk of cardiovascular disease |
| KR20180073597A (ko) | 2015-11-06 | 2018-07-02 | 젬파이어 세러퓨틱스 인코포레이티드 | 혼합 이상지질혈증의 치료 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
-
1998
- 1998-11-12 NZ NZ503982A patent/NZ503982A/en unknown
- 1998-11-20 BR BR9813542-2A patent/BR9813542A/pt not_active Application Discontinuation
- 1998-11-20 AT AT98960278T patent/ATE285762T1/de not_active IP Right Cessation
- 1998-11-20 CA CA002304612A patent/CA2304612A1/en not_active Abandoned
- 1998-11-20 DK DK98960278T patent/DK1045691T3/da active
- 1998-11-20 JP JP2000538687A patent/JP2002508320A/ja active Pending
- 1998-11-20 HU HU0004547A patent/HUP0004547A3/hu unknown
- 1998-11-20 ES ES98960278T patent/ES2230733T3/es not_active Expired - Lifetime
- 1998-11-20 KR KR1020007006355A patent/KR20010033003A/ko not_active Ceased
- 1998-11-20 AU AU15915/99A patent/AU754089B2/en not_active Ceased
- 1998-11-20 PL PL98341066A patent/PL341066A1/xx unknown
- 1998-11-20 PT PT98960278T patent/PT1045691E/pt unknown
- 1998-11-20 DE DE69828442T patent/DE69828442T2/de not_active Expired - Lifetime
- 1998-11-20 IL IL13534998A patent/IL135349A0/xx unknown
- 1998-11-20 EP EP98960278A patent/EP1045691B1/en not_active Expired - Lifetime
- 1998-11-20 WO PCT/US1998/024679 patent/WO1999030704A1/en not_active Ceased
- 1998-12-09 HN HN1998000185A patent/HN1998000185A/es unknown
- 1998-12-10 ZA ZA9811348A patent/ZA9811348B/xx unknown
- 1998-12-10 CR CR5926A patent/CR5926A/es not_active Application Discontinuation
- 1998-12-10 MY MYPI98005579A patent/MY118381A/en unknown
- 1998-12-11 PA PA19988464601A patent/PA8464601A1/es unknown
- 1998-12-11 CO CO98073828A patent/CO4970816A1/es unknown
- 1998-12-11 SV SV1998000146A patent/SV1998000146A/es not_active Application Discontinuation
- 1998-12-11 AR ARP980106321A patent/AR017851A1/es unknown
- 1998-12-11 PE PE1998001207A patent/PE20000017A1/es not_active Application Discontinuation
- 1998-12-11 GT GT199800196A patent/GT199800196A/es unknown
- 1998-12-11 UY UY25299A patent/UY25299A1/es not_active Application Discontinuation
-
2000
- 2000-04-14 IS IS5445A patent/IS2150B/is unknown
- 2000-06-09 CU CU20000140A patent/CU20000140A7/es unknown
- 2000-06-09 NO NO20002966A patent/NO20002966L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002508320A5 (enExample) | ||
| JP2002501887A5 (ja) | アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用 | |
| JP2004521894A5 (enExample) | ||
| Muramatsu et al. | Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin | |
| JP2005504092A5 (enExample) | ||
| RU2003126184A (ru) | Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов | |
| CA2536187C (en) | Pharmaceutical composition comprising a combination of metformin and a statin | |
| WO2001068096A2 (en) | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | |
| JP2004517916A5 (enExample) | ||
| RU2003126187A (ru) | Применение замещенных азетидинонов для лечения ситостеролемии | |
| JP2004532868A5 (enExample) | ||
| JP2002525321A5 (ja) | カテーテルによる血管再生を予防または遅らせる医薬組成物の製造のためのコレステロール低下剤の使用 | |
| EP1045691B1 (en) | Statin-carboxyalkylether combinations | |
| ZA200102230B (en) | Method for preventing or delaying catheter-based revascularization. | |
| JP2007512347A5 (enExample) | ||
| RU2351329C2 (ru) | Ингибиторы кинуренин 3-гидроксилазы для лечения диабета | |
| Sharif et al. | Cough induced by quinapril with resolution after changing to fosinopril | |
| JP2003524582A5 (enExample) | ||
| JP2002506818A5 (enExample) | ||
| US8557835B2 (en) | Statin-carboxyalkylether combinations | |
| JP2005522490A5 (enExample) | ||
| US20020103252A1 (en) | Statin-carboxyalkylether combinations | |
| NZ502874A (en) | Antihyperlipidemic statin-lp(a) inhibitor combinations | |
| EP1358879A1 (en) | Antilipemic agents | |
| JP2004083588A5 (enExample) |